1-4 of 4
Thomas Meinicke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Vlado Perkovic, Robert Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T. George, Odd Erik Johansen, Christoph Wanner
Journal: Diabetes Care
Diabetes Care 2020;43(8):1803–1812
https://doi.org/10.2337/dc20-0279
Published: 22 May 2020
View article titled, Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Open the PDF for Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial in another window
Journal Articles

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes

Samy Hadjadj, Julio Rosenstock, Thomas Meinicke, Hans J. Woerle, Uli C. Broedl
Journal: Diabetes Care
Diabetes Care 2016;39(10):1718–1728
https://doi.org/10.2337/dc16-0522
Published: 04 August 2016
View article titled, Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
Open the PDF for Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C. Broedl, Hans J. Woerle, on behalf of the EMPA-REG MET Trial Investigators
Journal: Diabetes Care
Diabetes Care 2014;37(6):1650–1659
https://doi.org/10.2337/dc13-2105
Published: 10 May 2014
View article titled, Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Open the PDF for Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

Hans-Ulrich Häring, MD, Ludwig Merker, MD, Elke Seewaldt-Becker, PHD, Marc Weimer, PHD, Thomas Meinicke, MD, Hans J. Woerle, MD, Uli C. Broedl, MD, on behalf of the EMPA-REG METSU Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(11):3396–3404
https://doi.org/10.2337/dc12-2673
Published: 15 October 2013
View article titled, Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: <subtitle>A 24-week, randomized, double-blind, placebo-controlled trial</subtitle>
Open the PDF for Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: <subtitle>A 24-week, randomized, double-blind, placebo-controlled trial</subtitle> in another window
Includes: Supplementary data